Cardiff Oncology, Inc.CRDFNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P14
Within normal range
vs 5Y Ago
-6.3x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
2025-4.13%
202412.16%
202321.21%
202256.00%
202154.66%
20200.65%
201936.73%
20183.56%
2017-47.47%
201641.66%